Monitoring of PSA changes and assessment of the diagnostic value of PSA growth rates in patients with prostate cancer after radical prostatectomy
https://doi.org/10.17650/1726-9776-2007-3-3-68-72
Abstract
Objective. To define the prognostic value of the growth rate (GR) in the level of prostate-specific antigen (PSA) after radical prostatectomy (RPE).
Materials and methods. The data on 48 patients who underwent RPE in 1999—2006, in whom a biochemical recurrence was verified on the basis of the results of PSA monitoring, were retrospectively analyzed. PSA GR was calculated for each patient. Correlation analysis using the major predictors was also made.
Results. During a follow-up, overall and tumor-specific survivals were 91,7 and 93,8%, respectively. Five-year relapse-free survival calculated by the Kaplan-Meier method was 67%. PSA GR proved to be an independent predictor of relapse-free survival. Generalization was more common at a PSA GR of > 2 ng/ml/year while a PSA GR of 1,0—2,0 ng/ml/year is more typical of the development of a localized recurrence.
Conclusion. Analysis of post-PRE PSA GR makes it possible to predict the postoperative course of prostate cancer, to reveal its early progression, and to perform therapy in due time. For early diagnosis of its clinical progression, it is expedient to assess a combination of predictors, by making up progression-risk groups.
About the Authors
P. P. PyanykhRussian Federation
N. V. Vorobyev
Russian Federation
K. M. Nyushko
Russian Federation
References
1. Злокачественные новообразования в России в 2004 году (заболеваемость и смертность). Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М.; 2006. с. 98.
2. D'Amico A., Chen M., Roehl K. et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Eng J Med 2004;351:125—35.
3. D'Amico A., Moul J., Carroll P. et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 2004:172:S42—S47.
4. Daskivich T.J., Kantoff W.K. Prostate specific antigen doubling time (PSA-DT) and velocity (PSA-V) provide independent prognostic information in androgen independent prostate cancer (AIPC) patients receiving chemotherapy. J Clin Oncol 2006;24(18 Suppl):4616.
5. Sengupta S., Myers R., Slezak J. et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005:174:2191—6.
6. Roberts S., Blute М.L., Bergstralh E.J. et al. Скорость прироста и время удвоения ПСА как предсказатель клинической прогрессии после РПЭ. Urology (S.G.R., M.L.B., H.Z.) и Раздел Biostatistics (E.J.B., J.M.S.), Mayo Клиника, Rochester, Minn. Отдел Urology, Mayo Клиника, Rochester, MN 55905.
7. Zagars G., Pollock A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 1997:44:213—21.
8. Lam J.S., Belldegrun A.S. Using PSA kinetics to stratify risk of prostate cancer progression. Source: Urology Times. Originally published: September 1, 2005.
9. Dotan Z.A., Bianco F.I. Jr., Rabbani F. et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol 2005;23(9):1962—8.
10. Алексеев Б.Я. Лечение локализованного и местно-распространенного РПЖ. Автореф. дис. … докт. мед. наук. М.; 2006.
Review
For citations:
Pyanykh P.P., Vorobyev N.V., Nyushko K.M. Monitoring of PSA changes and assessment of the diagnostic value of PSA growth rates in patients with prostate cancer after radical prostatectomy. Cancer Urology. 2007;3(3):68-72. (In Russ.) https://doi.org/10.17650/1726-9776-2007-3-3-68-72